卡培他滨相关基因多态性与手足综合征关系的研究进展

doi:10.11904/j.issn.1002-3070.2018.02.012

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (2): 149-153.doi: 10.11904/j.issn.1002-3070.2018.02.012

卡培他滨相关基因多态性与手足综合征关系的研究进展

李响, 刘铎, 吴东媛, 范晓凡, 张娟综述, 董梅审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2018-01-04 出版日期:2018-04-28 发布日期:2018-05-09
通讯作者: 董梅,E-mail:13804567370@163.com
作者简介:李响,女,(1995-),硕士研究生,从事肿瘤药学方面的研究。
基金资助:
中国医疗手牵手工程委员会、北京医学奖励基金会(编号:YJHYXKYJJ-703);海燕基金-面上项目(编号:JJMS2014-01)

Research progress of relationship between capecitabine related gene polymorphisms and hand-foot syndrome

LI Xiang, LIU Duo, WU Dongyuan, FAN Xiaofan, ZHANG Juan, DONG Mei

Harbin Medical University Cancer Hospital,Harbin 150081,Chian

Received:2018-01-04 Online:2018-04-28 Published:2018-05-09

摘要/Abstract

摘要： 近年来,卡培他滨被广泛应用于临床,手足综合征(Hand and foot syndrome,HFS)是卡培他滨的剂量限制性毒性之一,常表现为手、足部的麻木,感觉迟钝,麻刺感,皮肤肿胀或红斑,脱屑、水泡或严重疼痛。它的发生严重影响了患者的化疗效果及日常生活。卡培他滨代谢酶的基因突变在药物疗效和不良反应方面扮演重要角色,尤其是CDA、CES、TP、DPD、TYMS、MTHFR的基因多态性与HFS的关系被广泛研究并取得了一定的进展。本文对卡培他滨代谢酶与HFS的关系进行综述,为确定卡培他滨化疗引起HFS的生物靶点提供参考。

关键词: 卡培他滨, 不良反应, 手足综合征, 基因多态性

Abstract: In recent years,capecitabine is widely used in clinical practice.Hand-foot syndrome is a dose-limiting toxicity,often manifested as numbness in the hands and feet,sensation of dullness,tingling,skin swelling or erythema,scaling,blisters or serious pain.Its occurrence has seriously affected the chemotherapy effect and daily life of patients.Genetic mutations of capecitabine metabolic enzymes play an important role in the drug efficacy and side-effect.In particular,the relationship between gene polymorphisms of CDA,CES,TP,DPD,TYMS,MTHFR and hand-foot syndrome has been widely investigated and achieved by researchers.This article reviews the relationship between capecitabine metabolizing enzymes and hand-foot syndrome in order to provide a reference for identifying the biological target of hand-foot syndrome caused by capecitabine chemotherapy.

Key words: Capecitabine, Adverse effects, Hand-foot syndrome, Gene polymorphism

中图分类号:

R968

李响, 刘铎, 吴东媛, 范晓凡, 张娟, 董梅. 卡培他滨相关基因多态性与手足综合征关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 149-153.

LI Xiang, LIU Duo, WU Dongyuan, FAN Xiaofan, ZHANG Juan, DONG Mei. Research progress of relationship between capecitabine related gene polymorphisms and hand-foot syndrome[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 149-153.

参考文献

1 侯婷,宋琼,任太娟,等.两种方法护理卡培他滨致手足综合征的疗效比较[J].分子影像学杂志,2017,40(2):239-241.
2 李洁,李忠.中医药防治卡培他滨所致手足综合征的研究进展[J].中医药信息,2012,29(4):166-168.
3 Nikolaou V,Syrigos K,Saif MW.Incidence and implications of chemotherapy related hand-foot syndrome[J].Expert Opin Drug Saf,2016,15(12):1625-1633.
4 Reichardt P,von Minckwitz G,Thuss PC,et al.Multicenter phase II study of oral capecitabine(Xeloda)in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy[J].Ann Oncol,2003,14(8):1227-1233.
5 Abushullaih S,Saad ED,Munsell M,et al.Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with Capecitabine:a single-institution experience[J].Cancer Invest,2002,20(1):3-10.
6 李玺,姜华,郭卫平,等.卡培他滨引起的手足综合征发病特点与治疗观察[J].中华临床医师杂志,2011,5(6):1781-1783.
7 郭千弘,马建瓴,张烔,等.卡培他滨与5-氟尿嘧啶引起手足综合征的临床观察[J].中国医药指南,2013,11(31):36-37.
8 Gao J,He Q,Hua D,et al.Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel[J].Clin Transl Oncol,2013,15(8):619-625.
9 童竹月,王彬彬.手足综合征的最新研究进展[J].浙江临床医学,2017,19(3):581-583.
10 Queckenberg C,Erlinghagen V,Baken BC,et al.Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations[J].Cancer Chemother Pharmacol,2015,76(5):1081-1091.
11 Lou Y,Wang Q,Zheng J.Possible pathways of capecitabine induced hand foot syndrome[J].Chem Res Toxicol,2016,29(10):1591-1601.
12 Mercier C,Dupuis C,Blesius A,et al.Early severe toxicities after capecitabine intake:possible implication of a cytidine deaminase extensive metabolizer profile[J].Cancer Chemother Pharmacol,2009,63(6):1177-1180.
13 Dahan L,Ciccolini J,Evrard A,et al.Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake:pharmacogenetic implications[J].J Clin Oncol,2012,30(4):41-44.
14 Caronia D,Martin M,Sastre J,et al.A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J].Clin Cancer Res,2011,17(7):2006-2013.
15 Pellicer M,García-González X,García MI,et al.Identification of new SNPs associated with severe toxicity to capecitabine[J].Pharmacol Res,2017,120:133-137.
16 García-González X,Cortejoso L,García MI,et al.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer[J].Oncotarget,2015,6(8):6422-6430.
17 Martín M,Martínez N,Ramos M,et al.Standard versus continuous administration of capecitabine in metastatic breast cancer(GEICAM/2009-05):a randomized,non inferiority phase II trial with a pharmacogenetic analysis[J].Oncologist,2015,20(2):111-112.
18 Hamzic S,Kummer D,Milesi S,et al.Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity[J].Clin Pharmacol Ther,2017,102(5):796-804.
19 Lindskog EB,Derwinger K,Gustavsson B,et al.Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer[J].BMC Clin Pathol,2014,14(1):25.
20 Huang L,Chen F,Chen Y,et al.Thymidine phosphorylase gene variant,platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines[J].Sci Rep,2014,4:5697.
21 Rosmarin D,Palles C,Pagnamenta A,et al.A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS[J].Gut,2015,64(1):111-120.
22 Yap YS,Kwok LL,Syn N,et al.Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine induced hand-foot syndrome:a randomized clinical trial[J].JAMA Oncol,2017,3(11):1538-1545.
23 Hammad H,Sarkar M,Subbarayan PR,et al.Thymidylate synthase 5′UTR polymorphic allele distribution in south florida population[J].J Cancer Ther,2012,3(2):173-176.
24 Thomas F,Hoskins JM,Dvora A,et al.Detection of the G＞C SNP and rare mutations in the 28 bp repeat of TYMS using gel-based capillary electrophoresis[J].Pharmacogenomics,2010,11(12):1751-1756.
25 Rosmarin D,Palles C,Church D.Genetic of toxicity from capecitabine and other fluorouracil based regimens:investigation in the QUASAR2 study,systematic review,and meta-analysis[J].J Clin Oncol,2014,32(10):1031-1039.
26 Matsusaka S,Lenz HJ.Pharmacogenomics of fluorouracil-based chemotherapy toxicity[J].Expert Opin Drug Metab Toxicol,2015,11(5):811-821.
27 Iacopetta B.Methyl-group metabolism and response of colorectal cancer to 5-fluorourail[J].Crit Rev Oncog,2006,12(1/2):115-126.
28 Loganayagam A,Arenas Hernandez M,Corrigan A,et al.Pharmacogenetic variants in the DPYD,TYMS,CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity[J].Br J Cancer,2013,108(12):2505-2515.
29 Roberto M,Romiti A,Botticelli A.Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine[J].Eur J Clin Pharmacol,2017,73(2):157-164.
30 Sharma R,Hoskins JM,Rivory LP,et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients[J].Clin Cancer Res,2008,14(3):817-825.

[1]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[2]	陈龙综述, 钱诚审校. 血管内皮生长因子基因多态性与乳腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 284-286.
[3]	崔岩, 戴洪双, 向大林, 陈辉, 王迪. 输尿管导管在复杂盆腔肿瘤手术中预防输尿管损伤的应用[J]. 实用肿瘤学杂志, 2015, 29(6): 497-500.
[4]	陈杰(综述),侯恩存(审校). 贝伐单抗联合XELOX方案治疗转移性结直肠癌的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 157-161.
[5]	叶小红, 张沂平. 非小细胞肺癌常见靶向药物的毒副反应研究进展[J]. 实用肿瘤学杂志, 2010, 24(2): 182-185.
[6]	刘磊, 顾曼玲. DX方案与XELOX方案一线治疗晚期胃癌疗效比较[J]. 实用肿瘤学杂志, 2010, 24(1): 62-63.
[7]	张明奎, 蒋华, 孙运良. 伊立替康联合卡培他滨治疗晚期结直肠癌的临床观察[J]. 实用肿瘤学杂志, 2009, 23(5): 451-453.
[8]	岳晓龙, 刘文明. CPT-11联合CAP与5-Fu/CF治疗晚期大肠癌的临床观察[J]. 实用肿瘤学杂志, 2009, 23(4): 336-338.
[9]	马景光, 邢丽娜, 刘晓, 董广璐, 刘晓滨, 魏星. 卡培他滨联合奈达铂同步放化疗宫颈复发癌[J]. 实用肿瘤学杂志, 2009, 23(4): 346-348.
[10]	蔡晓敏, 齐晓燕, 罗青, 皮秀梅, , 陈春玲. 芬太尼透皮贴剂治疗中、重度癌痛68例临床疗效观察[J]. 实用肿瘤学杂志, 2008, 22(6): 532-533.
[11]	林朝春;叶珠赛;孙秀琴. 消化道肿瘤抑郁患者对化疗不良反应的影响与护理对策[J]. 实用肿瘤学杂志, 2008, 22(05): 468-469.
[12]	施兵;张秀兵;徐健. XELOX方案与OLF方案治疗晚期结直肠癌的临床观察[J]. 实用肿瘤学杂志, 2007, 21(06): 525-526.
[13]	孙艳丽;卢振霞;王立波. 长春瑞滨联合卡培他滨治疗转移性乳腺癌30例临床观察[J]. 实用肿瘤学杂志, 2005, 19(01): 9-11.
[14]	刘慧杰;董明;王兰;高华;袁媛. 胃蛋白酶原C基因多态性在胃癌家系成员中的分布[J]. 实用肿瘤学杂志, 2001, 15(03): 163-165.

卡培他滨相关基因多态性与手足综合征关系的研究进展

Research progress of relationship between capecitabine related gene polymorphisms and hand-foot syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价